#### **Supporting Information for**

#### Original article

Structure–activity relationship of pyrazol-4-yl-pyridine derivatives and identification of a radiofluorinated brobe for imaging the muscarinic acetylcholine receptor  $M_4$ 

Ahmed Haider<sup>a,†</sup>, Xiaoyun Deng<sup>a,b,†</sup>, Olivia Mastromihalis<sup>c,†</sup>, Stefanie K. Pfister<sup>a</sup>, Troels E. Jeppesen<sup>a</sup>, Zhiwei Xiao<sup>a</sup>, Vi Pham<sup>c,d</sup>, Shaofa Sun<sup>c</sup>, Jian Rong<sup>a</sup>, Chunyu Zhao<sup>a</sup>, Jiahui Chen<sup>a</sup>, Yinlong Li<sup>a</sup>, Theresa R. Connors<sup>f</sup>, April T. Davenport<sup>g</sup>, James B. Daunais<sup>g</sup>, Vahid Hosseini<sup>h</sup>, Wenqing Ran<sup>i</sup>, Arthur Christopoulos<sup>c,d</sup>, Lu Wang<sup>i</sup>, Celine Valant<sup>c,d,\*</sup>, Steven H. Liang<sup>a,\*</sup>

<sup>a</sup>Department of Radiology, Division of Nuclear Medicine and Molecular Imaging Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

<sup>b</sup>Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

<sup>c</sup>Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia

<sup>d</sup>Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville VIC 3052, Australia

<sup>e</sup>Hubei Collaborative Innovation Centre for Non-power Nuclear Technology, College of Nuclear Technology & Chemistry and Biology, Hubei University of Science and Technology, Xianning 437100, China

<sup>f</sup>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

<sup>g</sup>Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA

<sup>h</sup>Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA 90024, USA


<sup>i</sup>Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China


Received 22 January 2022; received in revised form 13 May 2022; accepted 22 June 2022 \*Corresponding authors. Tel./fax: +1 617 230 5491.


E-mail addresses: liang.steven@mgh.harvard.edu (Steven H. Liang).


Running title: Imaging muscarinic acetylcholine receptor M<sub>4</sub>

# $^{1}\mathrm{H}$ spectrum of compound 2

















# $^{1}\mathrm{H}$ spectrum of compound $\mathbf{6a}$








# $^{13}\mathrm{C}$ spectrum of compound 6a














 $^{13}\mathrm{C}$  spectrum of compound 8





# $^{1}\mathrm{H}$ spectrum of compound 9







# $^{13}\mathrm{C}$ spectrum of compound 9









 $^{1}\mathrm{H}$  spectrum of compound  $\mathbf{6b}$ 



 $^{13}\mathrm{C}$  spectrum of compound  $\mathbf{6b}$ 





 $^{1}\mathrm{H}$  spectrum of compound  $\mathbf{10}$ 




### $^{13}\mathrm{C}$ spectrum of compound 10












# $^{13}\mathrm{C}$ spectrum of compound 11













# $^{19}\mathrm{F}$ spectrum of compound 12














<sup>19</sup>F spectrum of compound 13




 $^{13}\mathrm{C}$  spectrum of compound 13




### **M1** Receptor



# **M2** Receptor



# M3 Receptor



# **M5** Receptor

